Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Pharmacokinetic Profile and Palatability of Atomoxetine Oral Solution in Healthy Japanese Male Adults.

Nakano M, Witcher J, Satoi Y, Goto T.

Clin Drug Investig. 2016 Nov;36(11):903-911.

2.

Comparative efficacy of methylphenidate and atomoxetine in the treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review and meta-analysis.

Rezaei G, Hosseini SA, Akbari Sari A, Olyaeemanesh A, Lotfi MH, Yassini M, Bidaki R, Nouri B.

Med J Islam Repub Iran. 2016 Feb 10;30:325. eCollection 2016.

4.

Pharmacological treatment for attention deficit hyperactivity disorder: functional outcomes in children and adolescents from non-Western countries.

Altin M, El-Shafei AA, Yu M, Desaiah D, Treuer T, Zavadenko N, Gao HY.

Drugs Context. 2013 Sep 13;2013:212260. doi: 10.7573/dic.212260. eCollection 2013 Sep 13.

5.

Prognostic factors of improvement in health-related quality of life in atomoxetine-treated children and adolescents with attention-deficit/hyperactivity disorder, based on a pooled analysis.

Montoya A, Quail D, Anand E, Cardo E, Alda JA, Escobar R.

Atten Defic Hyperact Disord. 2014 Mar;6(1):25-34. doi: 10.1007/s12402-013-0119-5. Epub 2013 Oct 20.

6.

Health-related quality of life and functional outcomes from a randomized, controlled study of lisdexamfetamine dimesylate in children and adolescents with attention deficit hyperactivity disorder.

Banaschewski T, Soutullo C, Lecendreux M, Johnson M, Zuddas A, Hodgkins P, Adeyi B, Squires LA, Coghill D.

CNS Drugs. 2013 Oct;27(10):829-40. doi: 10.1007/s40263-013-0095-5.

7.

Self-esteem evaluation in children and adolescents suffering from ADHD.

Mazzone L, Postorino V, Reale L, Guarnera M, Mannino V, Armando M, Fatta L, De Peppo L, Vicari S.

Clin Pract Epidemiol Ment Health. 2013 Jul 11;9:96-102. doi: 10.2174/1745017901309010096. Print 2013.

8.
10.
11.

Psychometric properties of the quality of life scale Child Health and Illness Profile-Child Edition in a combined analysis of five atomoxetine trials.

Schacht A, Escobar R, Wagner T, Wehmeier PM.

Atten Defic Hyperact Disord. 2011 Dec;3(4):335-49. doi: 10.1007/s12402-011-0066-y. Epub 2011 Oct 11.

13.

Self-esteem in adolescent patients with attention-deficit/hyperactivity disorder during open-label atomoxetine treatment: psychometric evaluation of the Rosenberg Self-Esteem Scale and clinical findings.

Dittmann RW, Wehmeier PM, Schacht A, Lehmann M, Lehmkuhl G.

Atten Defic Hyperact Disord. 2009 Dec;1(2):187-200. doi: 10.1007/s12402-009-0011-5. Epub 2009 Sep 23.

14.
15.

Atomoxetine treatment and ADHD-related difficulties as assessed by adolescent patients, their parents and physicians.

Dittmann RW, Wehmeier PM, Schacht A, Minarzyk A, Lehmann M, Sevecke K, Lehmkuhl G.

Child Adolesc Psychiatry Ment Health. 2009 Aug 24;3(1):21. doi: 10.1186/1753-2000-3-21.

16.

The quality of life of children with attention deficit/hyperactivity disorder: a systematic review.

Danckaerts M, Sonuga-Barke EJ, Banaschewski T, Buitelaar J, Döpfner M, Hollis C, Santosh P, Rothenberger A, Sergeant J, Steinhausen HC, Taylor E, Zuddas A, Coghill D.

Eur Child Adolesc Psychiatry. 2010 Feb;19(2):83-105. doi: 10.1007/s00787-009-0046-3. Epub 2009 Jul 26. Review.

17.

Atomoxetine improves patient and family coping in attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in Swedish children and adolescents.

Svanborg P, Thernlund G, Gustafsson PA, Hägglöf B, Schacht A, Kadesjö B.

Eur Child Adolesc Psychiatry. 2009 Dec;18(12):725-35. doi: 10.1007/s00787-009-0031-x. Epub 2009 May 23.

18.

Hypericum perforatum (St John's wort) for attention-deficit/hyperactivity disorder in children and adolescents: a randomized controlled trial.

Weber W, Vander Stoep A, McCarty RL, Weiss NS, Biederman J, McClellan J.

JAMA. 2008 Jun 11;299(22):2633-41. doi: 10.1001/jama.299.22.2633.

Supplemental Content

Support Center